Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term stability intervals.
| Brand name | DULOXETINE |
| Generic name | DULOXETINE |
| Active ingredient(s) | DULOXETINE HYDROCHLORIDE |
| Distributed by / for | Ajanta Pharma Ltd. |
| NDC | 27241-099-03 |
| Full product label | Duloxetine Delayed-Release Capsules, 60 mg, Rx Only, 30 capsules, Marketed by: Ajanta Pharma USA Inc., Bridgewater, NJ 08807, Made in India, NDC 27241-099-03 |
| Recalling firm | Ajanta Pharma Ltd. |
| Distribution | Nationwide within U.S |
| Quantity | 77,376 packs. |
| Recall initiated | 2026-04-29 |
| Report date | 2026-05-13 |
| Recall completed | — |
| Recall number | D-0515-2026 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Aurangabad India |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗